Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VA Changes Infliximab Biosimilars; Merck Formulary Win Could Drive Questions On Patient Switching

Executive Summary

Move from one infliximab biosimilar to another could illuminate safety concerns surrounding non-medical switching – or at least Janssen hopes so; VA's national formulary moved from Remicade to Pfizer's Inflectra in 2017.
Advertisement

Related Content

Momenta Is Exiting Biosimilars; Is That A Bellwether For Biosimilar Sentiment?
Biosimilars: Is Small Dip In Development Indicative Of Sustained Downward Trend?
Should Biosimilars Be Cheap? Sponsors Aren't So Sure
Prospect Of Biosimilar-To-Biosimilar Switching Spurs Call For Postmarketing Data
Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says
Biosimilar Legal Landscape: Lessons From 2017
Biosimilars: US FDA Education Campaign Is Non-Committal On Non-Medical Switching
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
Biosimilar Interchangeability May Be Losing Luster As Approval Goal
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124026

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel